Cannabics Pharmaceuticals

99 articles with Cannabics Pharmaceuticals

• Cannabics Pharmaceuticals Initiates In-Vivo Animal Studies for FDA Pre-IND Meeting Package

  12/21/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has initiated a series of proof of concept (POC), in-vivo , animal model studies to test its drug candidate RCC-33 on mice tr

• Cannabics Pharmaceuticals Founds Digestix Bioscience Inc., a Subsidiary for Treatment of Precancerous and Early Stage Neoplastic Local Tumors

  11/16/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has established a subsidiary, Digestix Bioscience Inc., a company dedicated to the development of medical devices and pharmace

• Cannabics Concludes a Pre-Clinical Study on Human Biopsies in Preparation for FDA pre-IND Meeting Request on Colorectal Cancer Drug Candidate RCC-33

  11/9/2020

  Cannabics Pharmaceuticals Inc., a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced that it has completed a pre-clinical study using its proprietary and novel RCC-33 formulation on human biopsies, obtained under a Helsinki Committee approved protocol.

• Cannabics Pharmaceuticals receives "Intention to Grant a European Patent" notice for its System and Method for High Throughput Screening of Cancer Cells patent application

  10/27/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has been informed by the European Patent Office that the examining division intends to grant the company a European Patent for

• Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33

  10/21/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has signed an agreement with a leading clinical quality and validation processes consultancy to oversee the preparation and submissi

• Cannabics Pharmaceuticals to Establish a Division for its Antitumor Drug Candidate RCC-33

  8/20/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it is establishing a dedicated division for the development of its Antitumor Drug Candidate RCC-33 for the treatment of colorectal cancer.

• Cannabics Pharmaceuticals Appoints Dr. Dana Ben-Ami Shor (MD), Gastroenterologist, to its Scientific Board of Advisors

  8/5/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Dr. Dana Ben-Ami Shor to its Scientific Board of Advisors.

• Cannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets

  7/14/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has initiated activities to penetrate European markets in order to offer a test based on its diagnostic platform to patients who suffer from cancer and a

• Cannabics Pharmaceuticals Appoints Dr. Erez Scapa, MD to its Scientific Board of Advisors

  6/16/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Dr. Erez Scapa to its Scientific Board of Advisors.

• Cannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers

  6/10/2020

  Cannabics Pharmaceuticals Inc.  (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has signed a Memorandum Of Understanding with Cannomed Medical Cannabis Industries Ltd. (TASE: CNMD), to develop cannabis cultivars targeted to treat c

• Cannabics Pharmaceuticals to Capitalize on Israel's Final Approval for the Export of Medical Cannabis

  5/26/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the Israeli government has granted final approval for the export of medi

• Cannabics Pharmaceuticals Files Provisional Patent on Composition and Method for Treating Colon Cancer With Cannabinoids

  5/6/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has filed a Provisional Patent Application with the US Patent & Trademark Office (USPTO) entitled "Composition and Method for Treating Colon Cancer with

• Cannabics Pharmaceuticals Appoints Prof. Zamir Halpern to Its Scientific Board of Advisors

  4/27/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Prof. Zamir Halpern to its Scientific Board of Advisors.

• Cannabics Pharmaceuticals Develops Novel Cannabis Formulation for the Treatment of Colon Cancer

  4/13/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has completed its preclinical development of a novel formulation containing cannabinoids which have demonstrated anti-tumor properties in studies held at the company's High Throughput Screening (HTS) research facility in Israel, which were focused on gastrointestinal cancers.

• Cannabics Pharmaceuticals Offers Its High Throughput Screening (HTS) Platform to the Israeli Health Authorities for SARS-CoV-2 Research

  3/18/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it is offering its High Throughput Screening (HTS) facility , in order to assist with  the Israeli national effort in researching and containing SARS-CoV

• Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma

  3/11/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has completed a scan of selected RCKMC's cannabis strains.

• Cannabics Pharmaceuticals Study Shows Cannabinoids CBNA and CBCA Cause Necrosis Similarly to their Non-acidic Form

  2/18/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the cannabinoids CBN (Cannabinol) and CBC (Cannabichromene) and their acidic form were shown to have necrotic effects on human colon cancer cells in a pre-clinical study held at the company's High Throughput Screening (HTS) facility in Israel. 

• Cannabics Pharmaceuticals Collaborates With RCKMC to Develop Cannabis Strains Targeting Gastrointestinal Cancers

  2/11/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has signed a Memorandum Of Understanding with RCK Medical Cannabis to develop cannabis chemovars targeted to treat gastro intestinal cancers.

• Cannabics Pharmaceuticals Study Shows Cannabinoids CBC and CBG Exhibit

  1/27/2020

  Cannabics Pharmaceuticals Inc. announced that in a series of tests conducted at the company's High Through-put Screening facility in Israel, it has been shown that the cannabinoids CBC and CBG both exhibit anti-tumor properties, tested on human Gastrointestinal Cancer Cells.

• Cannabics Pharmaceuticals Announces Cannabigerol (CBG) Shown to Have Anti-tumor Properties

  1/9/2020

  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that in a pre-clinical study held at the company's High Throughput Screening (HTS) lab facilities in Israel, preliminary findings show that the cannabinoid Cannabigerol (CBG) was shown to have a greater anti-tumor effect on human stomach and bone cancer cell lines compared to CBGA, the acidic form of the compound